Company / R&D Expense
Becton Dickinson R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.3B
FY2025
5-year range
$1.2B / $1.3B
FY2021-FY2025
Trend
+6.3%
vs FY2024
Sector context
#8 of 110
Health Care
What the data says
Among 110 Health Care companies, Becton Dickinson is in the top 7% for r&d expense. R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $1.3B.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +4.0%. Top quartile in the Health Care sector.
Improved from $1.2B to $1.3B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 110This company $1.3B Sector average $298.2M
▼
+324.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.0%, indicating consistent growth.
- In FY2025, r&d expense increased 6.3% year-over-year.
- Ranks #8 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.16 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +6.3% |
| FY2024 | $1.2B | -3.8% |
| FY2023 | $1.2B | -1.5% |
| FY2022 | $1.3B | -1.8% |
| FY2021 | $1.3B | +23.1% |
| FY2020 | $1.0B | -2.2% |
| FY2019 | $1.1B | +5.8% |
| FY2018 | $1.0B | +30.4% |
| FY2017 | $770.0M | -7.0% |
| FY2016 | $828.0M | +31.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026